|
 |
|
Deadline for submission of
nominations for the 2009 Benedict R. Lucchesi
Distinguished Lectureship in Cardiac Pharmacology is
September 15, 2008 |
|
Benedict R. Lucchesi Distinguished Lectureship in Cardiac
Pharmacology for 2009
Deadline for submission
of nominations is September 15, 2008 |
The Benedict R. Lucchesi Award in Cardiac
Pharmacology was established to honor Dr. Lucchesi’s lifelong
scientific contributions to our better understanding and
appreciation of pharmacological treatment and prevention of
cardiovascular disease and for his mentoring of countless prominent
functional (in vivo) cardiovascular pharmacologists.
The Benedict R. Lucchesi Award is a biennial award, consisting an
honorarium of $1,000, a custom-designed crystal bowl depicting the
named Lectureship, and up to $2,000 travel expenses including
registration to the annual spring ASPET meeting. A recipient will be
selected and invited to deliver a state-of-the-art lecture on recent
advances in the field of cardiac and electropharmacology at the
spring ASPET meeting (Division’s programming session). The
presentation of his/her research should be of
broad interest and contribute to the growth of the Cardiovascular
Pharmacology Division.
There are no restrictions on institutional affiliation, nationality,
or age of the candidate, but the recipient must be a member of the
ASPET. Nominations must be made by a member of the ASPET, and no
member may nominate more than one candidate per year. Final
selection of the recipient will
be made by the Award Committee of the Division for Cardiovascular
Pharmacology.
Nominations should consist of not more than five letters from
nominators describing the contributions
to cardiac and electropharmacology of the candidate that make
him/her eligible for this Award and
listing of his/her major contributions, together with a complete
curriculum vitae. To ensure
consideration, all information must be submitted electronically to:
Jane Nelson
jane.nelson@aspet.org, American Society for Pharmacology and
Experimental Therapeutics, 9650 Rockville Pike, Bethesda, MD
20814-3995 no later
than September 15, 2008. |
|